Andrew Dudum Sells 128,127 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 128,127 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $58.27, for a total value of $7,465,960.29. Following the completion of the sale, the chief executive officer now owns 97,687 shares of the company’s stock, valued at approximately $5,692,221.49. This trade represents a 56.74 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Andrew Dudum also recently made the following trade(s):

• On Friday, January 31st, Andrew Dudum sold 100,000 shares of Hims & Hers Health stock. The shares were sold at an average price of $35.22, for a total value of $3,522,000.00.
• On Thursday, January 23rd, Andrew Dudum sold 27,098 shares of Hims & Hers Health stock. The shares were sold at an average price of $30.08, for a total value of $815,107.84.
• On Tuesday, January 21st, Andrew Dudum sold 300 shares of Hims & Hers Health stock. The shares were sold at an average price of $30.00, for a total value of $9,000.00.
• On Thursday, January 16th, Andrew Dudum sold 36,460 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.09, for a total value of $987,701.40.
• On Monday, December 16th, Andrew Dudum sold 78,127 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.62, for a total value of $2,314,121.74.
• On Monday, December 2nd, Andrew Dudum sold 33,513 shares of Hims & Hers Health stock. The stock was sold at an average price of $33.38, for a total value of $1,118,663.94.

Hims & Hers Health Price Performance

NYSE:HIMS opened at $49.10 on Friday. Hims & Hers Health, Inc. has a fifty-two week low of $9.25 and a fifty-two week high of $72.98. The stock has a market capitalization of $10.73 billion, a PE ratio of 111.58 and a beta of 1.35. The business’s 50-day simple moving average is $35.05 and its 200-day simple moving average is $25.70.

Wall Street Analyst Weigh In

A number of brokerages recently commented on HIMS. BTIG Research began coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price objective for the company. Citigroup lowered Hims & Hers Health from a “neutral” rating to a “sell” rating and lifted their price objective for the stock from $24.00 to $25.00 in a research report on Friday, January 10th. Canaccord Genuity Group lifted their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday. Deutsche Bank Aktiengesellschaft boosted their target price on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. Finally, Morgan Stanley lowered Hims & Hers Health from an “overweight” rating to an “equal weight” rating and boosted their target price for the stock from $42.00 to $60.00 in a research report on Tuesday. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $28.53.

Hedge Funds Weigh In On Hims & Hers Health

Several institutional investors have recently modified their holdings of the business. SlateStone Wealth LLC lifted its holdings in shares of Hims & Hers Health by 4.0% during the 4th quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock valued at $257,000 after purchasing an additional 413 shares in the last quarter. Blume Capital Management Inc. lifted its stake in Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 600 shares in the last quarter. Summit Investment Advisors Inc. lifted its stake in Hims & Hers Health by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company’s stock valued at $480,000 after acquiring an additional 628 shares in the last quarter. Quest Partners LLC lifted its stake in Hims & Hers Health by 22.6% in the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after acquiring an additional 807 shares in the last quarter. Finally, Harbour Investments Inc. lifted its stake in Hims & Hers Health by 18.8% in the 4th quarter. Harbour Investments Inc. now owns 5,269 shares of the company’s stock valued at $127,000 after acquiring an additional 833 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.